Fibrodysplasia Ossificans Progressiva – a presentation of cases and literature review
DOI:
https://doi.org/10.15584/ejcem.2019.2.14Keywords:
clinical course, diagnostic difficulties, ectopic ossification, fibrodysplasia ossificans progressivaAbstract
Introduction. Fibrodysplasia ossificans progressiva (FOP) is a very rare inherited disease leading to progressive ectopic ossification of muscle and soft tissue and resulting in severe immobilisation and premature death. The mutations in ACVR1 gene that codes the 1A activin receptor which belongs to the family of bone morphogenetic proteins (BMPs) are leading to clinical symptoms.
Aim. In this raport we present 3 cases of paediatric FOP patients presenting varied clinical course of disease.
Description of the cases.
Case 1. A girl, currently 5 years old, was hospitalised for the first time at the age of 10 months with suspicion of a hyperplastic lesion of the left lumbar area. The time period between the first symptom, i.e. subcutaneous oedema, and the correct diagnosis was about 8 months. The symptom with key importance for the diagnosis was congenital deformities of the thumbs and big toes.
Case 2. A 6-year-old girl with a congenital hallux valgus in both feet, a small painless nodular lesion in the area of the distal metaphysis of the femur, limiting the flexion of the knee joint, was diagnosed in the third month of life.
Case 3. A three-year-old girl was diagnosed with congenital defects i.e. hallux valgus of both feet. The first symptoms of the disease occurred during her 14th month when an oedema of the subcutaneous tissue of the nape area was observed.
Conclusion. Until recently, there has been no efficient therapy which could slow down the natural course of the disease and currently the disease is treated as incurable. Of key importance from the perspective of patients is early diagnosis and, more importantly, preventing traumas, surgical procedures, intramuscular injections, sparing dental treatment and ensuring avoidance of airway tract infections.
Downloads
References
Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191-205.
Connor JM, Evans DA. Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet. 1982;19(1):35-39.
Kaplan FS, Fiori JL, de la Peña LS, et al. Dysregulation of BMP4 receptor trafficking and signaling in fibrodysplasia ossificans progressiva. Clinic Rev Bone Miner Metab. 2005;3:217.
Kaplan FS, Chakkalakal SA, Shore EM. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech. 2012;5(6):756-762.
Shen Q, Little SC, Xu M, et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest. 2009;119(11):3462- 3472.
Feldman G, Li M, Martin S, Urbanek M, et al. Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31. Am J Hum Genet. 2000;66(1):128-135.
Kaplan J, Kaplan FS, Shore EM. Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther. 2012;19(7):786-790.
Kaplan FS, Pignolo RJ, Shore EM. Granting immunity to FOP and catching heterotopic ossification in the Act. Semin Cell Dev Biol. 2016;49:30-36.
Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(2):437-48.
Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92(3):686-691.
Kaplan FS, Glaser DL. Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3:213-216.
Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.
Kaplan FS, Shen Q, Lounev V, et al. Skeletal metamorphosis in fibrodysplasia ossificans progressiva (FOP). J Bone Miner Metab. 2008;26(6):521-530.
Kaplan FS, Glaser DL, Shore EM, et al. The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab. 2005;3:213–216.
Kaplan FS, Xu M, Seemann P, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009;30(3):379-390.
Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol. 2010;6(9):518-527.
Nussbaum BL, Grunwald Z, Kaplan FS. Oral and dental health care and anesthesia for persons with fibrodysplasia ossificans progressiva. Clinic Rev Bone Miner Metab. 2005;3:239- 242.
Schaffer AA, Kaplan FS, Tracy MR, et al. Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressive are distinctly different from those in patients with Klippel-Feilsyndrome: clues from the BMP signaling pathway. Spine. 2005;30:1379-1385.
Cohen RB, Hahn GV, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am. 1993;75(2):215-219.
Scarlett RF, Rocke DM, Kantanie S, Patel JB, Shore EM, Kaplan FS. Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 2004;(423):275-279.
Connor JM, Evans DA. Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982;64(1):76-83.
Janati J, Aghighi Y, Tofighi A, Akhavan A, Behrouzan O. Radiologic findings in seven patients with fibrodysplasia ossificans progressiva. Arch Iran Med. 2007;10(1):88-90.
Sawyer JR, Klimkiewicz JJ, Iannotti JP, Rocke DM. Mechanism for superior subluxation of the glenohumeral joint in fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;(346):130-133.
Shore EM. Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another? Wiley Interdiscip Rev Dev Biol. 2012;1(1):153-165.
Beratis NG, Kaffe S, Aron AM, Hirschhorn K. Alkaline phosphatase activity in cultured skin fibroblasts from fibrodysplasia ossificans progressiva. J Med Genet. 1976;13(4):307-309.
Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics. 2008;121(5):e1295-300.
Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005;116(5):e654-61.
Glaser DL, Kaplan FS. Treatment considerations for the management of fibrodysplasia ossificans progressiva. Clinic Rev Bone Miner Metab. 2005;3:243-250.
Bonvento G. Early diagnosis and possible treatment of the fibrodysplasia ossificans progressive (FOP). Diseases. http: //flipper. diff. org /app/items /info/5995. (Access 02.12.2013).
Clementia reports the top-line results of its Phase 2 clinical trial for palovarotene in fibrodysplasia ossificans progressiva. www.clementiapharma.com. (Access 02.12.2013).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
